Activity of TGR-1202, a Novel Once-Daily Pi3K Delta Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. By admin / 05/30/2014
A Phase I Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (MAB) in B-Cell Lymphoma Patients with Prior Exposure to Rituximab. By admin / 05/30/2014
The PI3K Delta Inhibitor TGR-1202 Induces Cytotoxicity and Inhibits Phosphorylation of AKT in 17p Deleted and Non-17p Deleted CLL Cells in Vitro. By admin / 04/09/2014
The PI3K Delta Inhibitor TGR-1202 In Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines. By admin / 04/09/2014
The PI3K-d Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines. By admin / 12/10/2013
The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib are Highly Synergistic in Killing Human B- and T-Cell Lymphoma Cells. By admin / 12/10/2013
A Phase I Dose Escalation Study of TGR-1202, a Novel PI3K-d Inhibitor, For Patients with Relapsed or Refractory Hematologic Malignancies. By admin / 12/10/2013
The PI3k-delta inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro. By admin / 09/09/2013
Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal for Rituximab Relapsed/Refractory B-cell Malignancies. By admin / 06/14/2013
